Research Suggests Gout Drug Could Lower Diabetes Risk Among Veterans

by U.S. Medicine

December 6, 2015

NEW ORLEANS — Could a common drug used for gout lower the risk of diabetes?

That’s what a recent study in the journal Clinical Therapeutics endeavored to find out.1

The study team led by Tulane University researchers conducted a retrospective study of 27,876 adults with gout identified via the Veterans Integrated Services Network 16 data warehouse.

Patients in the study had up to 11 years of follow-up, from January 1999 through December 2010, and the final study sample consisted of 1,046 pairs of 1:1 propensity score-matched patients from the colchicine treated and control cohorts. The researchers’ focus was on time to first diabetes development since the first gout diagnosis was modeled.

Results indicate that, among the matched pairs, 234 veterans who had taken colchicine and 224 veterans who had never taken colchicine developed diabetes; the incidence rates were 38.95 and 39.02 per 1000 patient-years, respectively.

In Poisson and Cox proportional hazards regression, however, the risk of incident diabetes was reduced with increased duration of colchicine use, although the difference was not statistically significant. In further analysis, hazard ratio for incident diabetes among patients who had taken colchicine was 0.877 compared with those who had not taken colchicine.

“This study suggests a possible duration- or dose-related association between colchicine use and reduced risk of diabetes in adults with gout even though the risk reduction was not significant,” according to the study authors, who called for further studies to confirm their findings.

1 Wang L, Sawhney M, Zhao Y, Carpio GR, Fonseca V, Shi L. Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout. Clin Ther. 2015 Jun 1;37(6):1206-15. doi: 10.1016/j.clinthera.2015.03.010. Epub 2015 Apr 7. PubMed PMID: 25857595.

Comments are closed here.

Related Articles

Better Survival for NSCLC Patients Treated by Military Medicine

Does universal healthcare access provided by the MHS translate into improved patient outcomes for non-small cell lung cancer?

Increasing Usage of SSRIs for Dementia Symptoms

Emerging data has suggested effectiveness for selective serotonin reuptake inhibitors for treatment of behavioral and psychological symptoms of dementia.

U.S. Medicine Recommends

More From diabetes


Caution Urged in Use of Sulfonylureas in Some T2 Diabetes Patients with CAD

VA clinicians should exercise caution with use of sulfonylurea in some patients with co-morbid type 2 diabetes and cardiovascular disease, according to new research.


Hypoglycemia Concerns Help Drive Use of Continuous Glucose Monitoring at VA

As the VA increases its focus on minimizing hypoglycemia in veterans with type 2 diabetes, it expects that more physicians and veterans will consider using continuous glucose monitors to meet that goal.


Cautious Use of Prandial Insulin Urged for Older Veterans

A new VA study pointed out why prandial insulin should be used cautiously in older adults with complex comorbidities.


Adherence to New Medications Is Critical for Veterans With Diabetes

How important is adherence to oral medications in reducing complications for veterans with diabetes?


VA Research Links Global Air Pollution to Diabetes Risk

Air pollution, even at levels technically falling into safe ranges, are associated with an increased risk of diabetes, according to a new study involving VA researchers.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up